UFP Technologies, Inc. — Q3 2015 Form 10-Q
Business context and reporting period. UFP Technologies designs and custom-converts foam, plastic, and natural-fiber products for medical, automotive, consumer, aerospace and defense, electronics, and industrial markets. This unaudited filing covers the three and nine months ended September 30, 2015; year-to-date comparisons are against the same 2014 period.
Financial results and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Net sales | $34.441 million | $35.406 million | $104.917 million | $104.040 million |
| Gross profit | $9.510 million | $9.752 million | $28.442 million | $28.474 million |
| Gross margin | 27.6% | 27.5% | 27.1% | 27.4% |
| Operating income | $3.055 million | $3.098 million | $9.110 million | $9.080 million |
| Net income | $1.992 million | $2.066 million | $5.917 million | $5.988 million |
| Diluted EPS | $0.28 | $0.29 | $0.82 | $0.84 |
- Cash flow: Nine-month operating cash flow was $9.247 million, versus $6.852 million a year earlier. Capital expenditures were $13.003 million, primarily for manufacturing equipment and a new Massachusetts manufacturing and headquarters building. Investing activities used $12.972 million; financing activities used $0.972 million.
- Balance sheet and debt: Cash was $29.355 million at September 30, down from $34.052 million at December 31, 2014. Total assets were $120.237 million and stockholders’ equity was $101.555 million. Total debt was approximately $2.1 million, including $1.009 million current and $1.112 million long-term. The $40 million revolving facility had no borrowings outstanding; the company reported compliance with its covenants.
- Other: The effective tax rate was approximately 35%. The company repurchased 29,559 shares for $587,000 during the first nine months under a $10 million authorization.
Material changes versus the prior comparable period
- Q3 sales declined 2.7%, while nine-month sales rose 0.8%. The quarterly decline reflected lower electronics, industrial, and aerospace and defense sales, partly offset by medical growth. The aerospace and defense comparison was affected by a large, low-margin Q3 2014 order.
- Medical sales rose to $13.781 million in Q3 from $12.523 million and to $42.574 million year to date from $37.623 million. Nine-month automotive sales also increased; electronics, industrial, and consumer markets were softer.
- Q3 gross margin edged up, attributed to favorable business mix and lower material and labor costs as a share of sales. Nine-month gross margin declined, primarily due to a decrease in sales of lower-material-content molded-fiber packaging products.
- Q3 SG&A decreased 5.7% to $5.604 million, primarily reflecting lower salaries, benefits, and commissions following consolidations. Nine-month SG&A was broadly unchanged at $18.404 million.
Outlook, risks, and unusual items
- Management expects approximately $2.1 million of one-time costs for Northeast plant consolidations, including about $2.0 million in cash charges, and approximately $1.0 million in annual savings. About $875,000 of Northeast restructuring costs had been recorded through September 30. Raritan, Haverhill, and Byfield moves were expected to be completed by year-end 2015; the Georgetown relocation by March 31, 2016.
- Management cited strong medical-market demand and said it had secured or was finalizing several long-term contracts, including a five-year agreement estimated at $45 million that would more than double annual revenue with a key customer. The filing does not clearly specify whether that agreement was fully finalized.
- The company planned further capacity additions and said available resources, operating cash flow, and its credit facility were expected to fund requirements, including capital spending, through the next 12 months. It also may pursue acquisitions. No specific revenue or earnings guidance was provided.
- Risks include whether plant consolidations deliver expected savings, whether new customer contracts are finalized, timely and cost-effective implementation and utilization of new equipment, and future operating performance and cash generation. Management noted deferred tax assets could require a valuation allowance if expected future taxable income declines. No material changes to previously disclosed risk factors or market risks were reported.
- The company reported no material off-balance-sheet arrangements other than operating leases and no material changes to contractual obligations outside the ordinary course of business.
Important facts for investors to verify
- Whether the estimated $45 million medical contract was finalized, and its timing and revenue contribution.
- Progress, remaining costs, completion dates, and realized savings from the Northeast consolidations.
- Returns and utilization from the substantial equipment and facility investment, given year-to-date capital spending exceeded operating cash flow.
- Cash conversion and working-capital trends, including receivables, inventory, and accrued expenses.
- Remaining capacity under the share-repurchase authorization and any subsequent repurchases.